Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
New products, merger to drive Glaxo - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Aug 2, 2000

    New products, merger to drive Glaxo

    Glaxo seems to be a new high these days. The proposed merger with SmithKline is likely to come through sooner than expected. The company has reported very healthy results for the second quarter with a topline growth of over 27%, when the overall pharmaceutical industry is growing by not more than 10% per annum. Most important, Glaxo’s parent seems willing to introduce new products through the listed company.

    What however seems to be driving the company’s stock seems to be the sooner–than–expected merger with SmithKline.

    The merged company with a market share of 7% will be way ahead of competitors Cipla and Ranbaxy. It will have brands such as Iodex, Augmentin (an amoxycillin–clavulanic acid combination), Engerix (Hepatitis B vaccine), Zevit and Livogen (vitamins and minerals), which will complement its prescription led product profile. Glaxo, at present, has a presence in a large number of therapy areas (over 60% of the market). It is a market leader in 80% of the segments in which the company operates and has a large portfolio of over 200 product packs. Besides, the company enjoys the trust of the medical profession. Its prescription brands such as Betnovate (dermatologicals), Zinetac (ranitidine), Becadexamin (vitamin) Cetzine (anti–histamine) are as well known as over the counter products in their own right. The company has a clean balance sheet and a first class management. Besides, the merged entity will also command an enviable marketing network that will go a long way in its attempt to increase market share.

    SmithKline Consumer has a presence in health food drinks through the brands ‘Horlicks’, ‘Viva’ and ‘Maltova’. Glaxo, on the other hand, has sold its brand ‘Farex’ which operated in a similar space a few year’s back. Since the parent’s operations are likely to be restricted to pharmaceuticals it is quite possible that the merged company in India could disinvest the healthfood operations. Another side effect of the impending merger is that Glaxo is likely to inherit SmithKline’s 100% subsidiary in India i.e. SmithKline Beecham Asia. Whether ‘Crocin’ ‘Tums’ and ‘Eno’ continue to remain a part of the parent’s 100% subsidiary will demonstrate the parent’s attitude towards the minority shareholders.

    As far as new products are concerned the company has lined up a slew of new launches over the next 12–18 months. Overall the company would continue to focus on the therapy areas of the future such as respiratory, anti–virals, osteoporosis and consolidate in dermatologicals, gastrointestinals and antibiotics.

    Glaxo's new products
    Brand Purpose Introduced
    Hepitec Hepatitis–B Yes
    Seretide Asthma Yes
    Lamictal Epilepsy No
    Valtrex Viral Infections No
    Epivir AIDS Yes
    Combivir AIDS Yes
    Zoderm Oxiconazole No
    Histofreezer Wart removal Yes

    Glaxo has posted a mixed performance over the last two year’s. However, the pending mergers with Burroughs Wellcome and SmithKline Beecham and its recent attempts to restructure its operations have the potential to rev up its performance in the coming year’s.



    Equitymaster requests your view! Post a comment on "New products, merger to drive Glaxo". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts